Surgical management of stage-2 medication-related osteonecrosis of the jaw with transplantation of human amniotic membrane: Preliminary results

J Stomatol Oral Maxillofac Surg. 2022 Jun;123(3):e28-e31. doi: 10.1016/j.jormas.2021.09.011. Epub 2021 Sep 23.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a drug adverse reaction. Seven osteonecrosis areas in 5 cases were treated with stage-2 MRONJ using human amniotic membrane (HAM) transplantation after sequestrectomy. Patients were evaluated in terms of infection (pain, erythema, and pus), mucosal coverage, and pain at 1, 2, 4, 8, and 12 weeks. Patients who showed improvement (total mucosal coverage, no sign of infection and pain) at the end of 12 weeks were followed up every 8 weeks. Also, radiographic examinations (panoramic radiography at every 8 weeks, cone-beam computed tomography at every 6 months) were performed to evaluate bone destruction. Complete mucosal closure was achieved in 6 necrosis sites. In only 1 patient, mucosal coverage was not achieved. No pain and infection relapse were observed during the follow-ups. HAM might be an effective material in terms of soft tissue healing and elimination of pain and infection for stage-2 MRONJ. Clinical Trials Registration Number: NCT04967963.

Keywords: Amniotic membrane; Bisphosphonates; MRONJ; Medication-related osteonecrosis of the jaw; Mucosal coverage.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amnion
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / diagnosis
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / surgery
  • Bone Density Conservation Agents* / adverse effects
  • Humans
  • Pain / chemically induced
  • Radiography, Panoramic

Substances

  • Bone Density Conservation Agents

Associated data

  • ClinicalTrials.gov/NCT04967963